More recently, in metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma has been shown the efficacy of a tumor necrosis factor-alpha TNF-α inhibitor (Marimastat), a Che-1 antagonist [15, 16]. The gene discussed is TNF; the disease is hepatocellular carcinoma.